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OBJECTIVE — Intensive insulin therapy (IIT) reduces morbidity and mortality in patients in
surgicalintensivecareunits.TheaimofthisstudyistoassesstheeffectofIITusingaclosed-loop
system in hepatectomized patients.
RESEARCH DESIGN AND METHODS — Patients were randomly assigned to receive
IIT using a closed-loop system: an artiﬁcial pancreas (AP group) or conventional insulin therapy
using the sliding-scale method (SS group).
RESULTS — The incidence of surgical-site infection in the AP group was signiﬁcantly lower
thanthatintheSSgroup.ThelengthofhospitalizationrequiredforpatientsintheAPgroupwas
signiﬁcantly shorter than that in the SS group.
CONCLUSIONS — TotalhospitalcostsforpatientsintheAPgroupweresigniﬁcantlylower
than for patients in the SS group. IIT using a closed-loop system maintained near-
normoglycemia and contributed to a reduction in the incidence of SSI and total hospital costs
due to shortened hospitalization.
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L
arge randomized trials in which the
use of tight blood glucose control
with intensive insulin therapy (IIT)
was compared with standard blood glu-
cosecontrolinsurgicalintensivecareunit
(ICU) patients have demonstrated that
strict control of postoperative blood glu-
cose levels not only signiﬁcantly reduced
patient mortality but also reduced mor-
bidity (1,2). These results helped initiate
several short-lived multicenter random-
ized control studies designed to evaluate
the beneﬁt of tight glycemic control with
IIT (3,4). Unfortunately, however, these
clinical trials were stopped early, mainly
because of the high incidence of hypogly-
cemia (10–17%) induced by IIT (5).
Considering the frequency of the use
of IIT in patients undergoing surgical
treatment in the ICU, we conducted a
prospective randomized controlled trial
to evaluate the postoperative condition of
thepatientsandtheeffectofaclosed-loop
artiﬁcialpancreas(6–9)ontightglycemic
control during IIT in hepatectomized
patients.
RESEARCH DESIGN AND
METHODS— Of the 91 people ap-
proached to take part in this prospective
randomized study, 88 agreed to partici-
pate. Patients were informed of the pur-
pose and details of the study, and written
consent was obtained from them before
enrollment. The study was approved by
the local ethics committee at the Kochi
Medical School and was carried out in ac-
cordance with the Helsinki Declaration.
All studies were performed between April
2007 and June 2008. We prospectively
divided patients into two groups: one for
whom glucose levels were controlled us-
ing a manual injection of insulin accord-
ing to the commonly used sliding scale
(SS group, n  44) (10) and a second
group that received programmed infu-
sionsofinsulindeterminedbythecontrol
algorithm of the closed-loop system (AP
group, n  44).
The primary end point of this study
was to determine whether the incidence
of SSI is reduced by perioperative tight
glycemic control. SSI was monitored just
after operation until discharge by the in-
fection control team at our institute. The
secondary end point was to evaluate the
costs during the hospital stay in each pa-
tient group.
Continuousvariablesarepresentedas
the mean  SD. Dichotomous variables
are presented as both number and per-
centage values. P  0.05 was considered
signiﬁcant. Data were analyzed using the
Student’s t test (two tailed), with dichot-
omous variables analyzed by the 
2 test
(two tailed) or Fisher’s exact test (two
tailed).
RESULTS— There was also no differ-
ence in the laboratory data, including nu-
tritional parameters, liver function,
fasting insulin concentration, and fasting
blood glucose level between the two
groups. Diabetes status was checked by a
diabetologist, and diabetic subjects all
had type 2 diabetes. The presence of a
previous medical history for diabetes was
equally distributed between the two
groups(31.8%intheSSgroupand38.6%
in the AP group, respectively). There was
no signiﬁcant predisposition to these op-
erative procedures between the two
groups.Theoperationtimeandestimated
volume of blood loss did not differ signif-
icantly between the two groups. Final
livertumordiagnoseswerehepatocellular
carcinoma in 29 patients and adenocarci-
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groups. There were no operative mortali-
ties (0%) 30 days after hepatic resection
in either group, and all patients were
discharged.
Neither group experienced hypogly-
cemia (40 mg/dl). Perioperative blood
glucose levels in the AP group were near
100mg/dl,butthoseintheSSgroupwere
150 mg/dl. Mean blood glucose levels
were adequately controlled by a closed-
loopglycemiccontrolsystem(Fig.1).The
percentages in blood glucose target at
very tight control (80–110 mg/dl) and
moderatelytightcontrol(140mg/dl)by
a closed-loop system during surgical ICU
were at least 60 and 85%, respectively
(Fig. 1) (5). In contrast, the postoperative
glucose control according to the sliding-
scale method was very poor. In all of the
SS group patients, the total insulin used
according to the routine sliding scale was
below 24 units. In the patients in the AP
group,atotalamountof17593unitsof
insulinwasconsumedforIITmanagedby
the STG-22 (a closed-loop glycemic con-
trol system, artiﬁcial pancreas) for 18 h
after the hepatic resection. The incidence
of SSI in the AP group was signiﬁcantly
lower than that in the SS group (P 
0.030). It is of note that patients in the AP
group required a signiﬁcantly shorter
hospitalization than patients in the SS
group (P  0.049). The total hospital ac-
tual costs, including the costs of using the
closed-loop system, for the original surgi-
cal admission of patients in the AP group
($16,407) were signiﬁcantly lower than
those for patients in the SS group
($21,879; P  0.047). None of the pa-
tients in the present study required oper-
ation-related readmission.
CONCLUSIONS— The risk of se-
vere hypoglycemia (glucose 40 mg/dl)
with IIT has been shown to increase from
5.1 to 18.7% in ICU studies (2,5,11). In
the present study, there were no occur-
rences of hypoglycemia. Clearly, we sup-
port a recent report that suggests the
development of accurate continuous
blood glucose–monitoring devices and
preferably closed-loop systems for com-
puter-assisted blood glucose control in
the ICU will help avoid hypoglycemia
(12).
A limited number of studies describ-
ing SSI after hepatic resection have re-
ported a wide-ranging incident rate of
10.8–26.0% (13–15). The total caloric
requirement was calculated according to
the Harris-Benedict equation. The results
of our study proposed that controlling
postoperative glucose levels using insulin
therapy and maintaining an adequate cal-
orielevelcontributedtoareductioninthe
incidence of SSI (2.3 vs. 18.2%). In the
current study, tight glycemic control was
performed for 18 h in patients with liver
resection at surgical ICU and excellent
glucosecontrolwassuccessfullyobserved
without hypoglycemia by using a closed-
loop system. We strongly believe that
perioperativetightglycemiccontrolforan
abbreviatedperiod(atleastfor18h)from
the postoperative early stage had a pre-
vention of postoperative infectious
morbidities.
When the overall costs during hospi-
talization were calculated, patients with
SSI had a crude median cost of $28,681
compared with $16,352 for uninfected
patients (P  0.001). This is the ﬁrst re-
port that demonstrates that perioperative
tight glycemic control might reduce the
incidence of postoperative SSI and de-
crease the total costs associated with hos-
pitalization for patients undergoing
hepatic surgery for liver neoplasm.
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